Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
REGÍSTRESE
Adoptive cell transfer (ACT)—including CAR T cells—has achieved remarkable success against some cancers, especially blood cancers. However, sometimes these T cells become inactivated prematurely. Dr. Villadangos found that this can happen is if the density of tumor cells is too high. He termed this phenomenon “stunning” and now he is determining what causes it. He’s also characterizing the broader relationship between tumor and immune cells and determining how they influence anti-cancer immune responses. Overall, Dr. Villadangos’ work will hopefully suggest ways to address stunning and augment current ACT approaches.
The University of Melbourne (Australia) | All Cancers | 2016
Comuníquese con nosotros
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).